Company intelligence / Profile preview

Epygenix Therapeutics

Paramus or Englewood Cliffs*, New Jersey, United Statesepygenix.com ↗

Ownership: Private
Development stage: Other

Overview

Epygenix advanced several small molecule candidates for rare genetic epilepsies into late-stage clinical development. Its lead compound, EPX‑100 (clemizole hydrochloride), demonstrated safety in Phase I and was positioned as a potential best-in-class therapy for Dravet syndrome after successful preclinical and early clinical studies. The company’s approach leverages unique animal models to identify both repurposed drugs and novel compounds targeting serotonin pathways—differentiating from standard GABAergic or ion channel therapies.

Therapeutic areas: Neurology
Modalities: Small moleculesRepurposed drugsNovel chemical entities
Industry: Biotech

Partnerships

University of California San Francisco/UCSF lab of Prof. Scott C. Baraban, PhD [collaborative technology originator].

Beyond the preview

Go deeper on Epygenix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epygenix Therapeutics.